By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Hologic, Inc.

Hologic, Inc. (0J5Q.L)

LSE Currency in USD
$63.72
-$0.08
-0.12%
Last Update: 17 Jul 2025, 14:41
$14.20B
Market Cap
20.10
P/E Ratio (TTM)
Forward Dividend Yield
$63.69 - $86.55
52 Week Range

0J5Q.L Stock Price Chart

Explore Hologic, Inc. interactive price chart. Choose custom timeframes to analyze 0J5Q.L price movements and trends.

There is nothing to show.

0J5Q.L Company Profile

Discover essential business fundamentals and corporate details for Hologic, Inc. (0J5Q.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Equipment & Services

IPO Date

29 Jan 2018

Employees

7.06K

CEO

Stephen P. MacMillan

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

0J5Q.L Financial Timeline

Browse a chronological timeline of Hologic, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 29 Apr 2026

Upcoming earnings on 3 Feb 2026

Upcoming earnings on 3 Nov 2025

Upcoming earnings on 30 Jul 2025

Revenue estimate is $1.01B.

Earnings released on 1 May 2025

EPS came in at $1.03 surpassing the estimated $1.02 by +0.98%, while revenue for the quarter reached $1.01B, missing expectations by -1.94%.

Earnings released on 5 Feb 2025

EPS came in at $0.87 falling short of the estimated $1.02 by -15.10%, while revenue for the quarter reached $1.02B, missing expectations by -0.05%.

Earnings released on 5 Nov 2024

EPS came in at $0.76 falling short of the estimated $1.01 by -25.05%, while revenue for the quarter reached $987.90M, beating expectations by +0.99%.

Earnings released on 30 Jul 2024

EPS came in at $0.82 falling short of the estimated $1.02 by -19.31%, while revenue for the quarter reached $1.01B, beating expectations by +0.96%.

Earnings released on 3 May 2024

EPS came in at $0.72 falling short of the estimated $0.98 by -26.89%, while revenue for the quarter reached $1.02B, beating expectations by +1.60%.

Earnings released on 4 Mar 2024

EPS came in at $1.03 surpassing the estimated $0.95 by +8.42%, while revenue for the quarter reached $1.01B, beating expectations by +2.40%.

Earnings released on 10 Nov 2023

EPS came in at $0.37 falling short of the estimated $0.84 by -56.36%, while revenue for the quarter reached $945.30M, beating expectations by +0.56%.

Earnings released on 1 Aug 2023

EPS came in at -$0.16 falling short of the estimated $0.89 by -118.45%, while revenue for the quarter reached $984.40M, beating expectations by +2.52%.

Earnings released on 2 May 2023

EPS came in at $0.88 falling short of the estimated $0.88 by -0.23%, while revenue for the quarter reached $1.03B, beating expectations by +7.33%.

Earnings released on 2 Feb 2023

EPS came in at $0.75 falling short of the estimated $0.91 by -17.54%, while revenue for the quarter reached $1.07B, beating expectations by +6.91%.

Earnings released on 29 Sept 2022

EPS came in at $0.47 falling short of the estimated $0.63 by -24.80%, while revenue for the quarter reached $953.30M, beating expectations by +10.58%.

Earnings released on 29 Jun 2022

EPS came in at $0.90 surpassing the estimated $0.71 by +27.04%, while revenue for the quarter reached $1.00B, beating expectations by +11.00%.

Earnings released on 26 Apr 2022

EPS came in at $1.80 surpassing the estimated $1.60 by +12.50%, while revenue for the quarter reached $1.44B, beating expectations by +11.39%.

Dividend declared on 15 Mar 2022

A dividend of $0.29 per share was announced, adjusted to $0.29.

Earnings released on 2 Feb 2022

EPS came in at $1.95 surpassing the estimated $1.32 by +47.73%, while revenue for the quarter reached $1.47B, beating expectations by +23.31%.

Earnings released on 1 Nov 2021

EPS came in at $1.04, while revenue for the quarter reached $1.17B.

Earnings released on 25 Sept 2021

EPS came in at $1.28, while revenue for the quarter reached $1.32B.

Earnings released on 27 Mar 2021

EPS came in at $2.38, while revenue for the quarter reached $1.54B.

Earnings released on 26 Dec 2020

EPS came in at $2.50, while revenue for the quarter reached $1.61B.

Earnings released on 26 Sept 2020

EPS came in at $1.88, while revenue for the quarter reached $1.35B.

0J5Q.L Stock Performance

Access detailed 0J5Q.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
0J5Q.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
0J5Q.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More